Using filters to reduce chemotherapy side effects
Official title: Endovascular Filtration to Change Drug Biodistribution (ELOCUTION)
Funded at University of California, San Francisco · NIH-11034975 · Data updated 2026-11-12
This study is working on new devices that can help remove chemotherapy drugs from the bloodstream during treatment, making it safer and more effective for patients by reducing side effects while still targeting tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 21, 2025 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $670,440 |
| NIH project number | 1R01EB036603-01 |
| Project ID | NIH-11034975 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients receiving intra-arterial chemotherapy for liver or brain tumors.
✕Less likely to help
Patients who are not undergoing locoregional chemotherapy or those with conditions not related to the targeted organs may not benefit from this research.
What this research studies
This research focuses on developing innovative catheter-based devices that can filter out chemotherapy drugs from the bloodstream during treatment. By using real-time x-ray imaging, these filters aim to minimize the systemic toxicity associated with chemotherapy while still allowing the drugs to target tumors effectively. The project will involve creating and testing prototypes of these filters in laboratory settings and animal models to ensure their safety and effectiveness. The ultimate goal is to improve the delivery of chemotherapy to specific organs while reducing harmful side effects.
Why it matters
Potential benefit: If successful, this research could significantly reduce the side effects of chemotherapy for patients undergoing locoregional infusion therapy.
How similar studies have gone: Previous research has shown promise in using similar filtration techniques to reduce drug toxicity, indicating potential for success in this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Hetts, Steven William — University of California, San Francisco
- Study coordinator: Hetts, Steven William
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.